GO:0009263 deoxyribonucleotide biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009263 describes the chemical reactions and pathways that build deoxyribonucleotides, the activated precursors of DNA [1,2].
• The pathway supplies the four dNTPs (dATP, dTTP, dGTP, dCTP) required for DNA replication and repair, and its imbalance causes mutagenesis and cancer [2,4].
• Ribonucleotide reductase (RNR) is the rate-limiting enzyme that converts ribonucleotides to deoxyribonucleotides and is tightly regulated across the cell cycle.
• Hypoxia, oxidative stress and alkylating agents distort deoxyribonucleotide pools and increase mutation frequency [1,3,8].
• CRISPR knockout, point-mutation, knock-in and overexpression models are powerful tools to dissect deoxyribonucleotide biosynthetic genes and their disease roles [2,5].
• Understanding this pathway supports cancer therapy, antiviral drug design and genome-stability research [2,4].
Description
Deoxyribonucleotide biosynthetic process (GO:0009263) is the set of biochemical reactions that produce deoxyribonucleotides, the building blocks of DNA [1,2]. These molecules consist of a deoxyribose sugar linked to a nitrogenous base and esterified with one or more phosphate groups, and they are essential for DNA replication, repair and recombination [2,4]. Because DNA synthesis depends on a balanced supply of all four deoxyribonucleoside triphosphates (dNTPs), the pathway is a central node in cell-cycle control and genome stability [2,5]. Research over several decades has shown that deoxyribonucleotide metabolism is not merely a housekeeping function; it is a regulated network that influences mutation rates, cancer development and responses to chemotherapy [2,4]. For example, altered dNTP pools can promote mutagenesis and drive tumor progression, while inhibition of the pathway is a validated strategy in anticancer and antiviral therapy [1,2]. The pathway also intersects with oxygen sensing, as hypoxic conditions challenge DNA replication by limiting deoxyribonucleotide availability. For researchers, GO:0009263 provides a precise ontology anchor for interpreting gene function, designing CRISPR screens and linking metabolic enzymes to disease phenotypes [2,5]. This article summarizes the definition, mechanism, key genes, regulation, disease relevance and experimental models for studying deoxyribonucleotide biosynthesis.
deoxyribonucleotide biosynthetic process At A Glance
| GO ID | GO:0009263 |
|---|---|
| GO term | deoxyribonucleotide biosynthetic process |
| Ontology | biological_process |
| Synonym | deoxyribonucleotide anabolism; deoxyribonucleotide biosynthesis; deoxyribonucleotide formation; deoxyribonucleotide synthesis |
| Major function | Production of deoxyribonucleotides (dNTPs) for DNA replication, repair and recombination |
| Key enzymes | Ribonucleotide reductase (RNR), thymidylate synthase, dihydrofolate reductase, nucleoside diphosphate kinase |
| Pathway inputs | Ribonucleotides, folate cofactors, glutamine, ATP |
| Cellular location | Cytoplasm and mitochondria (in eukaryotes) |
| Related processes | DNA replication (GO:0006260), pyrimidine deoxyribonucleotide biosynthesis, purine deoxyribonucleotide biosynthesis |
What Is GO:0009263?
In simple terms, GO:0009263 describes how cells make the deoxyribonucleotide building blocks of DNA. According to the QuickGO definition, it encompasses the chemical reactions and pathways resulting in the formation of a deoxyribonucleotide, a compound consisting of a deoxyribonucleoside (a base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar. This process includes both de novo synthesis and salvage routes that ultimately yield deoxyribonucleoside mono-, di- and triphosphates [1,2].
Why Is deoxyribonucleotide biosynthetic process Important in Cell Biology?
Deoxyribonucleotide biosynthesis is essential because it supplies the exact precursors needed for faithful DNA replication and repair [2,4]. When this pathway is perturbed, cells experience dNTP pool imbalances that increase mutation rates, sensitize tumors to chemotherapy and contribute to mitochondrial dysfunction and skin pathologies [1,2,7]. Moreover, the pathway is a target for antiviral and anticancer drugs, and its regulation is closely tied to cell-cycle progression and hypoxic stress [3,5].
• Provides dNTPs for DNA replication and repair, maintaining genome integrity [2,4].
• dNTP pool imbalance is a direct source of mutagenesis and a driver of cancer [1,2].
• Ribonucleotide reductase is a validated target for anticancer and antiviral therapies.
• Hypoxic tumor microenvironments challenge deoxyribonucleotide supply and DNA replication.
• Alkylating agents can modify deoxyribonucleotides, leading to carcinogenesis.
• Mitochondrial dysfunction affecting deoxyribonucleotide metabolism contributes to skin diseases.
• Mutation biases in mammalian DNA replication are linked to deoxyribonucleotide availability.
• The pathway is a rich source of metabolic and enzymatic drug targets [2,4].
What Happens During deoxyribonucleotide biosynthetic process?
De novo synthesis of deoxyribonucleotides
In simple terms: Cells build deoxyribonucleotides from simpler molecules in a multi-step process.
The de novo pathway starts with ribonucleotides, which are converted to their deoxy forms by ribonucleotide reductase (RNR). This enzyme reduces the 2'-OH group of ribonucleoside diphosphates (NDPs) to produce deoxyribonucleoside diphosphates (dNDPs), which are then phosphorylated to dNTPs by nucleoside diphosphate kinase [2,5]. The pathway requires reducing equivalents provided by thioredoxin or glutaredoxin systems.
Salvage pathways
In simple terms: Cells can also recycle deoxyribonucleosides from degraded DNA to make deoxyribonucleotides.
Salvage enzymes such as deoxycytidine kinase, thymidine kinase and hypoxanthine-guanine phosphoribosyltransferase (HPRT) phosphorylate deoxyribonucleosides to their corresponding monophosphates, which then enter the dNTP pool [2,4]. These routes are especially important in tissues with low de novo synthesis, such as the brain and lymphocytes.
Regulation of dNTP pools
In simple terms: The cell carefully controls how much of each deoxyribonucleotide is made to avoid mistakes during DNA copying.
dNTP pools are regulated by feedback inhibition of RNR and by allosteric control that balances the four dNTPs. Imbalances lead to misincorporation and mutagenesis, and are associated with cancer and mitochondrial diseases [1,2,7]. The S-phase checkpoint and ATR signaling also coordinate dNTP supply with DNA replication.
Compartmentalization and mitochondrial dNTP synthesis
In simple terms: Deoxyribonucleotide production happens in different parts of the cell, including mitochondria.
In eukaryotes, deoxyribonucleotide biosynthesis occurs in the cytoplasm and mitochondria, with distinct enzymes for each compartment [2,7]. Mitochondrial dNTP pools are maintained by salvage enzymes and a dedicated RNR-independent pathway, and defects cause mitochondrial DNA depletion syndromes.
Impact of hypoxia and oxidative stress
In simple terms: Low oxygen and oxidative stress can disrupt deoxyribonucleotide production and DNA replication.
Hypoxia inhibits ribonucleotide reductase and limits dNTP supply, causing replication stress and genomic instability. Oxidized deoxyribonucleotides can be incorporated into DNA, leading to mutations and cancer. These conditions are common in solid tumors and influence treatment response.
Key Genes Involved in GO:0009263 deoxyribonucleotide biosynthetic process
The following genes and proteins are central to deoxyribonucleotide biosynthetic process (GO:0009263) and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Ribonucleotide reductase subunit M1; catalytic subunit | Target for anticancer drugs; regulates dNTP pools |
| RRM2 | Ribonucleotide reductase subunit M2; radical-generating subunit | Cell-cycle regulated; overexpressed in cancers |
| RRM2B | p53-inducible RNR subunit; mitochondrial dNTP synthesis | Mutations cause mitochondrial DNA depletion |
| TYMS | Thymidylate synthase; converts dUMP to dTMP | Target of 5-fluorouracil; essential for dTTP synthesis |
| DHFR | Dihydrofolate reductase; regenerates tetrahydrofolate | Target of methotrexate; supports thymidylate synthesis |
| TK1 | Thymidine kinase 1; salvage of thymidine | Marker of cell proliferation; upregulated in cancers |
| DCK | Deoxycytidine kinase; salvage of deoxycytidine | Activates nucleoside analogs used in cancer and antiviral therapy |
| NDPK | Nucleoside diphosphate kinase; phosphorylates dNDPs to dNTPs | Maintains dNTP balance; linked to metastasis |
| GUK1 | Guanylate kinase; phosphorylates dGMP to dGDP | Supports dGTP synthesis |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase 1 | Provides PRPP for purine deoxyribonucleotide synthesis |
| ATIC | AICAR transformylase/IMP cyclohydrolase | Bifunctional enzyme in purine biosynthesis |
| GART | Phosphoribosylglycinamide formyltransferase | Purine de novo synthesis |
| CAD | Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, dihydroorotase | First steps of pyrimidine synthesis |
| CTPS1 | CTP synthase 1; converts UTP to CTP | Provides CTP for dCTP synthesis |
| NME1 | Nucleoside diphosphate kinase A | Suppresses metastasis; maintains dNTP pools |
| NME2 | Nucleoside diphosphate kinase B | Regulates dNTP pools and cell proliferation |
| DUT | Deoxyuridine triphosphatase; hydrolyzes dUTP | Prevents uracil misincorporation into DNA |
| UNG | Uracil-DNA glycosylase; removes uracil from DNA | Base excision repair; counteracts dUTP misincorporation |
How Is deoxyribonucleotide biosynthetic process Regulated?
Deoxyribonucleotide biosynthesis is regulated at multiple levels. Ribonucleotide reductase (RNR) is controlled by allosteric feedback inhibition and by cell-cycle-dependent transcription, ensuring balanced dNTP pools. The p53 tumor suppressor regulates RRM2B and other pathway genes in response to DNA damage. Hypoxia-inducible factors (HIFs) modulate dNTP metabolism under low oxygen, and the ATR checkpoint coordinates dNTP supply with replication fork progression. Additionally, oncogenic signaling through mTOR and MYC can upregulate nucleotide synthesis to support proliferation.
deoxyribonucleotide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RRM1 | Cancer; drug resistance | Knockout and point-mutation models in cancer cell lines |
| RRM2 | Cancer; cell-cycle dysregulation | Overexpression and inducible knockout models |
| RRM2B | Mitochondrial DNA depletion syndrome | Knock-in of patient mutations in iPSCs |
| TYMS | Cancer; 5-FU resistance | CRISPR knockout and knock-in of resistance alleles |
| DCK | Leukemia; nucleoside analog sensitivity | Knockout in leukemia cell lines |
Cancer and mutagenesis
Altered deoxyribonucleotide metabolism is a hallmark of cancer. dNTP pool imbalances increase mutation rates and drive tumorigenesis, and RNR overexpression is common in many cancers [1,2]. Oxidized deoxyribonucleotides can be incorporated into DNA, causing mutations that contribute to cancer development. Consequently, inhibitors of RNR and other pathway enzymes are used in chemotherapy.
Mitochondrial DNA depletion syndromes
Mutations in RRM2B and other genes involved in mitochondrial deoxyribonucleotide synthesis cause mitochondrial DNA depletion syndromes, which present with severe neuromuscular and multisystem disorders. These conditions highlight the importance of compartmentalized dNTP pools for mitochondrial genome maintenance.
Hypoxia and tumor microenvironment
Hypoxic conditions in solid tumors impair deoxyribonucleotide biosynthesis, leading to replication stress and genomic instability. This can influence sensitivity to chemotherapy and radiotherapy, and targeting the pathway may improve treatment outcomes.
Alkylating agent-induced carcinogenesis
Alkylating agents can modify deoxyribonucleotides and DNA bases, leading to mutations and cancer. The deoxyribonucleotide biosynthetic pathway interacts with DNA repair mechanisms to mitigate these effects, and defects in this interplay increase cancer risk.
From deoxyribonucleotide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RRM1 affect dNTP pools and DNA replication? | CRISPR knockout in HeLa or HCT116 cells |
| How do point mutations in RRM2B cause mitochondrial depletion? | Knock-in of patient mutations in iPSC-derived fibroblasts |
| Can overexpression of RRM2 drive tumorigenesis? | Doxycycline-inducible overexpression in mouse xenografts |
| What is the role of TYMS in 5-FU resistance? | CRISPR knockout and point-mutation knock-in in colorectal cancer cells |
| How does hypoxia alter deoxyribonucleotide metabolism? | CRISPR knockout of HIF targets under hypoxic conditions |
| Does DCK mediate nucleoside analog cytotoxicity? | Knockout in leukemia cell lines and primary cells |
How to Study the deoxyribonucleotide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Intracellular dNTP concentrations | Assessing pathway activity after CRISPR edits |
| CRISPR knockout screens | Gene essentiality and drug resistance | Identifying novel regulators of dNTP synthesis |
| Stable isotope labeling | Metabolic flux through deoxyribonucleotide pathways | Tracing de novo synthesis in cancer cells |
| RNA-seq | Transcriptional changes in pathway genes | Evaluating compensatory responses to gene knockout |
| Proteomics | Protein expression and post-translational modifications | Validating CRISPR knock-in and overexpression models |
| Live-cell imaging | DNA replication dynamics and cell-cycle progression | Visualizing replication stress under hypoxia |
| Comet assay | DNA damage and repair | Linking dNTP imbalance to genome instability |
| Mitochondrial DNA copy number qPCR | Mitochondrial genome maintenance | Modeling RRM2B-related depletion syndromes |
dNTP pool quantification
Mass spectrometry-based methods (LC-MS/MS) are used to measure intracellular dNTP concentrations, providing direct readouts of deoxyribonucleotide biosynthetic activity [2,5]. These methods are essential for assessing the impact of CRISPR edits on pathway flux.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes required for deoxyribonucleotide biosynthesis and for resistance to antimetabolites. Such screens have uncovered synthetic lethal interactions with RNR inhibitors and other pathway drugs.
Metabolic labeling and imaging
Stable isotope labeling with 13C-glucose or 15N-glutamine followed by mass spectrometry traces deoxyribonucleotide synthesis flux. Fluorescent nucleotide analogs and live-cell imaging can visualize DNA replication dynamics in edited cells.
Transcriptomics and proteomics
RNA-seq and proteomics reveal how CRISPR perturbations alter expression of deoxyribonucleotide biosynthetic genes and related pathways [2,5]. These approaches help identify compensatory mechanisms and regulatory networks.
How CRISPR Can Be Used to Study GO:0009263 deoxyribonucleotide biosynthetic process
Knockout
CRISPR knockout of genes such as RRM1, RRM2, TYMS or DCK allows researchers to determine their essentiality for deoxyribonucleotide biosynthesis and cell proliferation [2,5]. Knockout models reveal compensatory pathways and synthetic lethal interactions that can be exploited therapeutically.
Point Mutation
Point mutations in RRM2B or TYMS can be introduced to model patient-derived variants and study their impact on enzyme activity and dNTP pools. Such models help distinguish loss-of-function from hypomorphic alleles.
Knock-in
Knock-in of tagged or fluorescent versions of pathway enzymes (e.g., RRM1-GFP) enables live-cell imaging and proteomic analysis of deoxyribonucleotide biosynthetic complexes. Knock-in of disease-associated mutations in iPSCs provides isogenic models for mechanistic studies.
Overexpression
Overexpression of RRM2 or other pathway genes can drive dNTP pool expansion and promote tumorigenesis in xenograft models. Inducible overexpression systems allow temporal control of pathway activation and study of drug resistance.
How EDITGENE Supports deoxyribonucleotide biosynthetic process Research
Researchers studying deoxyribonucleotide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in dNTP supply, genome stability or drug response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for deoxyribonucleotide biosynthetic process research.
Frequently Asked Questions About deoxyribonucleotide biosynthetic process
What is GO:0009263 deoxyribonucleotide biosynthetic process?
GO:0009263 is a Gene Ontology biological process term describing the chemical reactions and pathways that produce deoxyribonucleotides, the building blocks of DNA [1,2].
What genes are involved in deoxyribonucleotide biosynthetic process?
Key genes include RRM1, RRM2, RRM2B, TYMS, DHFR, TK1, DCK, NME1, NME2, CAD and CTPS1, among others [2,4,5].
Why is deoxyribonucleotide biosynthesis important for cancer?
Imbalanced dNTP pools increase mutation rates and drive tumorigenesis, and many pathway enzymes are targets for anticancer drugs [1,2].
How is ribonucleotide reductase regulated?
RNR is regulated by allosteric feedback, cell-cycle-dependent transcription and p53 signaling to maintain balanced dNTP pools [5,7].
What happens when deoxyribonucleotide pools are imbalanced?
Imbalances cause misincorporation of nucleotides into DNA, leading to mutations, replication stress and genomic instability [1,2].
How does hypoxia affect deoxyribonucleotide biosynthesis?
Hypoxia inhibits ribonucleotide reductase and limits dNTP supply, causing replication stress in tumors.
What diseases are linked to defects in deoxyribonucleotide metabolism?
Cancer, mitochondrial DNA depletion syndromes and skin disorders associated with mitochondrial dysfunction are linked to pathway defects [2,7].
How can CRISPR be used to study deoxyribonucleotide biosynthetic genes?
CRISPR knockout, point mutation, knock-in and overexpression models allow functional dissection of pathway genes and their disease roles [2,5].
What methods measure deoxyribonucleotide levels?
LC-MS/MS, stable isotope labeling and dNTP pool assays are commonly used to quantify deoxyribonucleotides [2,4].
What is the role of thymidylate synthase in this pathway?
Thymidylate synthase converts dUMP to dTMP, a critical step for dTTP synthesis and DNA replication.
Conclusion
Deoxyribonucleotide biosynthetic process (GO:0009263) is a fundamental metabolic pathway that supplies the dNTPs required for DNA replication and repair. Its dysregulation is linked to cancer, mitochondrial diseases and mutagenesis, making it a rich area for therapeutic targeting [1,2,5]. CRISPR-based models are indispensable for dissecting the roles of pathway genes and for developing new treatments [2,7].
References
- 1. Mathews CK. 2017. Oxidized deoxyribonucleotides, mutagenesis, and cancer.. FASEB J 31(1):11-13 PMID: 27729413
- 2. Mathews CK. 2015. Deoxyribonucleotide metabolism, mutagenesis and cancer.. Nat Rev Cancer 15(9):528-39 PMID: 26299592
- 3. Ng N et al.. 2018. Challenges to DNA replication in hypoxic conditions.. FEBS J 285(9):1563-1571 PMID: 29288533
- 4. Mathews CK. 2014. Deoxyribonucleotides as genetic and metabolic regulators.. FASEB J 28(9):3832-40 PMID: 24928192
- 5. Guarino E et al.. 2014. Cellular regulation of ribonucleotide reductase in eukaryotes.. Semin Cell Dev Biol 30:97-103 PMID: 24704278
- 6. Wolfe KH. 1991. Mammalian DNA replication: mutation biases and the mutation rate.. J Theor Biol 149(4):441-51 PMID: 2062104
- 7. Feichtinger RG et al.. 2014. Mitochondrial dysfunction: a neglected component of skin diseases.. Exp Dermatol 23(9):607-14 PMID: 24980550
- 8. Saffhill R et al.. 1985. Mechanisms of carcinogenesis induced by alkylating agents.. Biochim Biophys Acta 823(2):111-45 PMID: 3907708
